Results 201 to 210 of about 2,291,402 (391)
Molecular Oncology, EarlyView.Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho +11 more
wiley +1 more source
Perspectives On Blood-Based Point-Of-Care Diagnostics
Open Access Emergency Medicine, 2019 Karalee Quig,1 Elizabeth G Wheatley,2 Matthew O’Hara2 1POC Testing Consultant, Aurora, CO, USA; 2Boston Strategic Partners, Inc., Boston, MA, USACorrespondence: Matthew O’HaraBoston Strategic Partners, Inc., 4 Wellington Street Suite 3 ...
Quig K, Wheatley EG, O’Hara M
doaj
Asthma care and factors affecting medication compliance: the patient's point of view [PDF]
, 2001 Maria Lindberg
openalex +1 more source
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
Molecular Oncology, EarlyView.GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski +19 more
wiley +1 more source
Exploring Biomarkers for Point of Care Bladder Cancer Detection [PDF]
, 2016 Bladder cancer is the 5th most common non-cutaneous human cancer in the United States. While effective methods of detecting bladder cancer are currently practiced, they are often expensive and invasive.
Walker, Cassandra M
core +1 more source
Facing Unmet Needs in Medicine Access at the Point of Care
Medicine Access @ Point of Care, 2017 Giulio Zuanetti
doaj +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source